Biotech Values

[DewDiligence]

JNJ/Medivir report that 79-86% of TMC435 patients in the four non-control arms of the phase-2b PILLAR study in the first-line setting stopped treatment at 24 weeks according to the response-guided protocol in the study:

http://finance.yahoo.com/news/Week24-Interim-Results-From-prnews-47168379.html?x=0&.v=1

The protocol of this study required that patients have undetectable VL from week 4 to week 20 in order to stop treatment at 24 weeks.